EUVIMEDEUVIMED entdecken
Übersichtsarbeit

When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?

Kim DeLeonardis, Lauren Hogan, Stephen A Cannistra, Deepa Rangachari, Nadine Tung

Journal of Oncology Practice · 2019-09 · 15 (9) · 465-473

DOI: 10.1200/jop.19.00201 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Oncology Practice, 2019-09. Verfasst von Kim DeLeonardis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Beth Israel Deaconess Medical Center, Boston, MA. Hauptthemen laut MEDLINE: Genetic Association Studies, Genetic Predisposition to Disease, Genetic Testing, Genomics. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Somatic genomic testing is rapidly becoming an integral part of care for patients with metastatic cancer. Extrapolation of these results beyond personalized cancer therapy is a skill being demanded of practicing oncologists without prior specialty in genetics. Up to 12% of tumor genomic profiling reports will reveal a germline pathogenic variant. Recognition of these germline variants is essential not only for optimal care of the patient with cancer but also to initiate cascade genetic testing in at-risk family members who also may carry the familial mutation. This article provides a concise and methodical, evidence-based strategy to guide oncology providers about how to identify genes associated with an inherited predisposition for cancer, determine the pathogenicity of variants reported within those genes, and understand the likelihood that these variants are of germline origin in a particular patient with cancer. Case examples are provided to illustrate clinical scenarios and facilitate application of the proposed approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic Association StudiesGenetic Predisposition to DiseaseGenetic TestingGenomicsGerm-Line MutationChromosomal InstabilityGenetic VariationHumansMedical OncologyNeoplasmsOncogenes

Autor:innen und Institutionen

  • Beth Israel Deaconess Medical Center, Boston, MA.

Zitieren

APA

DeLeonardis, K., Hogan, L., Cannistra, S. A., Rangachari, D., & Tung, N. (2019). When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?. Journal of Oncology Practice, 15(9), 465-473. https://doi.org/10.1200/jop.19.00201

Vancouver

DeLeonardis K, Hogan L, Cannistra SA, Rangachari D, Tung N. When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?. Journal of Oncology Practice. 2019;15(9):465-473. doi:10.1200/jop.19.00201

BibTeX
@article{DeLeonardis2019,
  author = {DeLeonardis, Kim and Hogan, Lauren and Cannistra, Stephen A and Rangachari, Deepa and Tung, Nadine},
  title = {When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?},
  journal = {Journal of Oncology Practice},
  year = {2019},
  volume = {15},
  number = {9},
  pages = {465--473},
  doi = {10.1200/jop.19.00201}
}
Kostenlos starten →